- Home
- CRVS
as 12-20-2024 4:00pm EST
Corvus Pharmaceuticals Inc is a clinical-stage biopharmaceutical engaged in developing drugs and antibodies that target the critical cellular elements of the immune system. It focuses on the development of immune modulator product candidates to treat COVID-19, T-cell lymphomas, other cancers, and autoimmune diseases. The company's primary product candidate is Soquelitinib (CPI-818), an oral, small-molecule drug that selectively inhibits ITK (interleukin-2-inducible T cell kinase). The other products include Ciforadenant (CPI-444) and Mupadolimab (CPI-006).
| Founded: | 2014 | Country: | United States |
| Employees: | N/A | City: | BURLINGAME |
| Market Cap: | 516.0M | IPO Year: | 2016 |
| Target Price: | $12.83 | AVG Volume (30 days): | 1.6M |
| Analyst Decision: | Buy | Number of Analysts: | 4 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -1.01 | EPS Growth: | N/A |
| 52 Week Low/High: | $1.30 - $10.00 | Next Earning Date: | 11-12-2024 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Latest Corvus Pharmaceuticals Inc. News
CRVS Breaking Stock News: Dive into CRVS Ticker-Specific Updates for Smart Investing
Benzinga
3 days ago
Why Is Corvus Pharmaceuticals Stock Trading Lower On Wednesday?
MT Newswires
4 days ago
Corvus Pharma Says Data From Atopic Dermatitis Study Shows Favorable Safety Profile; Shares Fall Pre-Bell
GlobeNewswire
4 days ago
Corvus Pharmaceuticals Announces Interim Data from Placebo-Controlled Phase 1 Clinical Trial of Soquelitinib for Atopic Dermatitis
BioPharma Dive
4 days ago
Tessera gets sickle cell funding; Corvus shares slide on eczema data
GlobeNewswire
4 days ago
Corvus Pharmaceuticals to Announce Interim Data from Placebo-Controlled Phase 1 Clinical Trial of Soquelitinib for Atopic Dermatitis on December 18, 2024
Simply Wall St.
11 days ago
Individual investors account for 50% of Corvus Pharmaceuticals, Inc.'s (NASDAQ:CRVS) ownership, while private equity firms account for 16%
MT Newswires
17 days ago
Corvus Pharmaceuticals Says Published Soquelitinib Data Highlights Novel Approach to Immunotherapy
GlobeNewswire
17 days ago
Corvus Pharmaceuticals Announces Publication of Biochemistry and Preclinical Data Demonstrating Potential of ITK Inhibition with Soquelitinib as a Novel Approach to Modulate Tumor Immunity
Compare CRVS vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "CRVS Corvus Pharmaceuticals Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.